Plasma melatonin is reduced in Huntington's disease

Area of Science:

• Neuroscience
• Endocrinology
• Chronobiology

Background:

• Huntington's disease (HD) is a neurodegenerative disorder affecting motor control, cognition, and mood.
• Sleep disturbances and circadian rhythm abnormalities are common in HD patients.
• Melatonin, a hormone produced by the pineal gland, regulates the sleep-wake cycle in response to light and darkness.

Purpose of the Study:

• To investigate alterations in melatonin production and circadian rhythm in individuals with Huntington's disease.
• To determine if melatonin levels differ between control subjects and those in premanifest or later stages of HD.
• To explore the potential of melatonin as a biomarker for HD progression and as a therapeutic agent for sleep disorders.

Main Methods:

• A 24-hour study was conducted analyzing melatonin levels in cohorts of control, premanifest HD, and stage II/III HD subjects.
• Circadian rhythm parameters, including mean concentration, acrophase, and onset of melatonin rise, were assessed.
• Pulsatile secretion patterns of melatonin were also evaluated.

Main Results:

• Significantly reduced mean and acrophase melatonin concentrations were found in stage II/III HD subjects compared to controls.
• A trend towards reduced mean and acrophase melatonin was observed in premanifest HD subjects.
• The onset of melatonin rise was significantly more spread out in both premanifest and stage II/III HD groups.
• A nonsignificant trend for reduced pulsatile melatonin secretion was noted.

Conclusions:

• Melatonin concentrations are demonstrably reduced in individuals with Huntington's disease.
• Altered melatonin patterns may explain the disrupted sleep and circadian behaviors characteristic of HD.
• These findings suggest that melatonin levels could serve as a biomarker for HD disease state and that melatonin therapy might alleviate sleep disorders in HD patients.